文献速递老年与多病共存慢病管理

利用严重不良事件评估随机对照试验的代表性

Assessing Representativeness of Randomised Controlled Trials using Serious Adverse Events.
PubMed 文献 · Ann Fam Med · 2023-01-01

Context: The applicability of randomised controlled trials of pharmacological agents to older people with frailty/multimorbidity is often uncertain, due to concerns that trials are not representative. However, assessing trial representativeness is challenging and complex.…

要点

  • 多数索引疾病的试验观察/预期SAE比值小于1,提示试验人群SAE发生少于常规医疗预期。
  • 共病数量较高与SAE/住院和死亡相关,但校正后多数试验比值仍小于1。
  • 观察/预期SAE比值或有助于评估试验结果对共病、衰弱常见老年人群的适用性。

核心结论

  • 试验参与者发生的SAE少于基于常规医疗中年龄、性别和疾病住院/死亡率的预期,证实了预测的代表性不足。
  • 该差异仅部分由多病共存差异解释。

研究设计与样本

  • 二次分析,纳入clinicaltrials.gov的483项试验(n=636,267),覆盖21种索引疾病,常规医疗对照来自SAIL数据库(n=2.3M)。
  • 利用SAIL数据按年龄、性别和索引疾病推导预期住院/死亡率,计算每项试验的观察/预期SAE比值,并在125项可获取个体数据的试验中额外校正共病数量。

主要发现

  • 21种索引疾病中12种的观察/预期SAE比值小于1,另6种点估计小于1但95%CI包含无效值。
  • 观察/预期SAE比值中位数为0.60(95%CI 0.56-0.65;COPD),四分位距为0.44(0.34-0.55;帕金森病)至0.88(0.59-1.33;IBD)。
  • 共病数量较高与SAE/住院和死亡相关;校正共病数量后,多数试验的观察/预期比值衰减但仍小于1。

关键数值与推荐

  • 观察/预期SAE比值小于1提示试验中SAE少于常规医疗预期。
  • 12/21索引疾病观察/预期SAE比值小于1;6/21点估计小于1但95%CI包含无效值。
  • 中位观察/预期SAE比值0.60(95%CI 0.56-0.65;COPD),四分位距0.44(0.34-0.55;帕金森病)至0.88(0.59-1.33;IBD)。

临床怎么用

  • 全科医生在将试验证据应用于共病和衰弱常见的老年人群时,可参考观察/预期SAE比值评估代表性。
  • 观察/预期SAE比值有助于判断试验结果对外推人群的适用性。

局限性

  • 观察/预期SAE比值分析仅部分校正共病数量,未完全解释代表性差异。
  • 仅在125项可获取个体数据的试验中额外校正共病数量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Context: The applicability of randomised controlled trials of pharmacological agents to older people with frailty/multimorbidity is often uncertain, due to concerns that trials are not representative. However, assessing trial representativeness is challenging and complex. Objectives: We explore an approach assessing trial representativeness by comparing rates of trial Serious Adverse Events (SAEs: most of which reflect hospitalisations/deaths) to rates of hospitalisation/death in routine care (which, in a trial setting, would be SAEs be definition). Study design: Secondary analysis of trial and routine healthcare data. Dataset and population: 483 trials (n=636,267) from clinicaltrials.gov across 21 index conditions. A routine care comparison was identified from SAIL databank (n=2.3M). Instrument: SAIL data were used to derive the expected rate of hospitalisations/deaths by age, sex and index condition. Outcomes: We calculated the expected number of SAEs for each trial compared to the observed number of SAEs (observed/expected SAE ratio). We then re-calculated the observed/expected SAE ratio additionally accounting for comorbidity count in 125 trials for which we accessed individual participant data. Results: For 12/21 index conditions the observed/expected SAE ratio was <1, indicating fewer SAEs in trials than expected given community rates of hospitalisations and deaths. A further 6/21 had point estimates <1 but the 95% CI included the null. The median observed/expected SAE ratio was 0.60 (95% CI 0.56-0.65; COPD) and the interquartile range was 0.44 (0.34-0.55; Parkinson's disease) to 0.88 (0.59-1.33; IBD). Higher comorbidity count was associated with SAEs/hospitalisations and deaths across index conditions. For most trials, the observed/expected ratio was attenuated but remained <1 after additionally accounting for comorbidity count. Conclusion: Trial participants experience fewer SAEs than expected based on age/sex/condition hospitalisation and death rates in routine care, confirming the predicted lack of representativeness. This difference is only partially explained by differences in multimorbidity. Assessing observed/expected SAE may help assess applicability of trial findings to older populations in whom multimorbidity and frailty are common.

来源:Ann Fam Med,查看原文。版权归原作者所有。

引用

  1. Hanlon P, McAllister D, Wild S, et al. Assessing Representativeness of Randomised Controlled Trials using Serious Adverse Events. Ann Fam Med. 2023. PMID: 36972531. doi:10.1370/afm.21.s1.3730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。